167 related articles for article (PubMed ID: 34174414)
1. Nose-to-brain delivery of phenytoin and its hydrophilic prodrug fosphenytoin combined in a microemulsion - formulation development and in vivo pharmacokinetics.
Pires PC; Fazendeiro AC; Rodrigues M; Alves G; Santos AO
Eur J Pharm Sci; 2021 Sep; 164():105918. PubMed ID: 34174414
[TBL] [Abstract][Full Text] [Related]
2. Intranasal fosphenytoin: The promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs.
Pires PC; Santos LT; Rodrigues M; Alves G; Santos AO
Int J Pharm; 2021 Jan; 592():120040. PubMed ID: 33157214
[TBL] [Abstract][Full Text] [Related]
3. Development and application of an ex vivo fosphenytoin nasal bioconversion/permeability evaluation method.
Antunes Viegas D; Rodrigues M; Francisco J; Falcão A; Alves G; Santos AO
Eur J Pharm Sci; 2016 Jun; 89():61-72. PubMed ID: 27106504
[TBL] [Abstract][Full Text] [Related]
4. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.
Fischer JH; Patel TV; Fischer PA
Clin Pharmacokinet; 2003; 42(1):33-58. PubMed ID: 12489978
[TBL] [Abstract][Full Text] [Related]
5. Fosphenytoin: a novel phenytoin prodrug.
Boucher BA
Pharmacotherapy; 1996; 16(5):777-91. PubMed ID: 8888074
[TBL] [Abstract][Full Text] [Related]
6. Fosphenytoin (Cerebyx).
Browne TR
Clin Neuropharmacol; 1997 Feb; 20(1):1-12. PubMed ID: 9037568
[TBL] [Abstract][Full Text] [Related]
7. Nanoemulsions and thermosensitive nanoemulgels of phenytoin and fosphenytoin for intranasal administration: Formulation development and in vitro characterization.
Pires PC; Peixoto D; Teixeira I; Rodrigues M; Alves G; Santos AO
Eur J Pharm Sci; 2020 Jan; 141():105099. PubMed ID: 31672614
[TBL] [Abstract][Full Text] [Related]
8. Fosphenytoin.
Luer MS
Neurol Res; 1998 Mar; 20(2):178-82. PubMed ID: 9522355
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and pharmacokinetics of fosphenytoin.
Browne TR; Kugler AR; Eldon MA
Neurology; 1996 Jun; 46(6 Suppl 1):S3-7. PubMed ID: 8649612
[TBL] [Abstract][Full Text] [Related]
10. Fosphenytoin in infants.
Takeoka M; Krishnamoorthy KS; Soman TB; Caviness VS
J Child Neurol; 1998 Nov; 13(11):537-40. PubMed ID: 9853645
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of fosphenytoin for the treatment of status epilepticus.
Popławska M; Borowicz KK; Czuczwar SJ
Expert Rev Neurother; 2015; 15(9):983-92. PubMed ID: 26289487
[TBL] [Abstract][Full Text] [Related]
12. Safety of fosphenytoin sodium.
Fierro LS; Savulich DH; Benezra DA
Am J Health Syst Pharm; 1996 Nov; 53(22):2707-12. PubMed ID: 8931812
[TBL] [Abstract][Full Text] [Related]
13. Fosphenytoin.
Eriksson K; Keränen T; Kälviäinen R
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):695-701. PubMed ID: 19473113
[TBL] [Abstract][Full Text] [Related]
14. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR
Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370
[TBL] [Abstract][Full Text] [Related]
15. Intravenous administration of fosphenytoin: options for the management of seizures.
Ramsay RE; DeToledo J
Neurology; 1996 Jun; 46(6 Suppl 1):S17-9. PubMed ID: 8649609
[TBL] [Abstract][Full Text] [Related]
16. Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin.
Löscher W; Reissmüller E; Ebert U
Epilepsy Res; 1998 Mar; 30(1):69-76. PubMed ID: 9551846
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.
Knapp LE; Kugler AR
J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747
[TBL] [Abstract][Full Text] [Related]
18. Fosphenytoin. Pharmacoeconomic implications of therapy.
Holliday SM; Benfield P; Plosker GL
Pharmacoeconomics; 1998 Dec; 14(6):685-90. PubMed ID: 10346419
[TBL] [Abstract][Full Text] [Related]
19. Increased shelf-life of fosphenytoin: solubilization of a degradant, phenytoin, through complexation with (SBE)7m-beta-CD.
Narisawa S; Stella VJ
J Pharm Sci; 1998 Aug; 87(8):926-30. PubMed ID: 9687335
[TBL] [Abstract][Full Text] [Related]
20. Hypocalcemia-like electrocardiographic changes after administration of intravenous fosphenytoin.
Keegan MT; Bondy LR; Blackshear JL; Lanier WL
Mayo Clin Proc; 2002 Jun; 77(6):584-6. PubMed ID: 12059129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
